A podcast for uro-oncologists developing a deeper understanding of the literature to ensure we apply the right evidence to the right patient.
…
continue reading
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care professionals. Learn more about our award-winning journal!
…
continue reading
Designed for residents and fellows to provide an overview of the clinical practice and evidence behind management of each individual tumor site. Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, cancer
…
continue reading
All Talk Oncology is a Cancer Podcast that empowers cancer patients through insightful conversations that reinforces confidence and certainty about their cancer condition. Transforming a terrifying experience into a manageable one, by arming patients with the understanding they need, and the ability to take control of their treatments through knowledge, allowing effective interaction with their medical team.
…
continue reading
Welcome to Integrative Oncology Talk! Where we discuss the latest science and opinions from leading voices in integrative oncology. Integrative oncology utilizes complementary therapies and lifestyle strategies to help those affected by cancer, using personalized approaches and evidence based recommendations. This podcast is hosted by Dr. Santosh Rao, a medical oncologist and integrative oncologist. Dr. Judith Lacey, a supportive care and integrative oncology physician. And Leigh Leibel (pro ...
…
continue reading
1
04_05 Muscle Invasive Bladder Cancer
29:16
29:16
Spela senare
Spela senare
Listor
Gilla
Gillad
29:16
1. Etymology, presentation, and work-up of bladder/urothelial cancer 2. Role of perioperative systemic therapy 3. Tri-modality therapy (bladder sparing approach) 4. Considerations for upper tract urothelial cancer Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.c…
…
continue reading
1
Bispecific T-cell Engager Antibody Brings Deep, Durable Remissions in R/R Multiple Myeloma
15:07
15:07
Spela senare
Spela senare
Listor
Gilla
Gillad
15:07
Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, brought robust clinical benefit to patients with relapsed or refractory multiple myeloma, including those in difficult-to-treat subgroups, in a multi-center, international study reported to the 2024 American Association for Cancer Research Annual Meeting. After…
…
continue reading
1
Exosome-Based Liquid Biopsy Promises Very Early Pancreatic Cancer Detection
12:50
12:50
Spela senare
Spela senare
Listor
Gilla
Gillad
12:50
An opportunity to detect pancreatic cancer at stages where early intervention can greatly extend life and even make cure possible seems to be on offer, according to findings from a study of a new liquid biopsy method based on so-called exosomes: subcellular molecules shed into the circulation by cancer cells. At the AACR Annual Meeting 2024 in San …
…
continue reading
1
Polyepitopic Personalized Vaccine Brought Durable Immune Responses & Clinical Benefit in Resected Head & Neck Cancers
13:00
13:00
Spela senare
Spela senare
Listor
Gilla
Gillad
13:00
Designed with the help of artificial intelligence to recognize multiple genetic features of each patient’s tumor, a small clinical trial of a personalized therapeutic vaccine has shown durable tumor-specific immune responses in patients with surgically resected HPV-negative head and neck squamous cell cancer. The vaccine also prevented relapse in s…
…
continue reading
1
Mesh-Supported Prepectoral Method of Breast Reconstruction After Breast Cancer Surgery
10:27
10:27
Spela senare
Spela senare
Listor
Gilla
Gillad
10:27
Higher rates of satisfaction and psychosocial well-being and low complication rates were reported by patients who had a new mesh-supported prepectoral method of breast reconstruction using titanized mesh pockets after their surgery for breast cancer. At the 14th European Breast Cancer Conference in Milan, Stefan Paepke, MD, from the Interdisciplina…
…
continue reading
1
Radiotherapy Boost Protects Young Patients With Early Breast Cancer, High Dose Boost Not Needed
8:38
8:38
Spela senare
Spela senare
Listor
Gilla
Gillad
8:38
The value of adding a radiation boost to postoperative radiotherapy for patients younger than 50 with early breast cancer has been confirmed by 10 years of data from the Young Boost trial conducted in the Netherlands. However, by randomizing patients between the standard radiation boost and a lower dose boost, the study demonstrated comparable effi…
…
continue reading
1
Breast-Conserving Therapy Effective for Ductal Carcinoma in Situ, But Questions Remain
15:40
15:40
Spela senare
Spela senare
Listor
Gilla
Gillad
15:40
A 30-year-long population-based study, reported at the 14th European Breast Cancer conference held in Milan, Italy, showed that breast-conserving therapy for ductal carcinoma in situ (DCIS) had become increasingly effective in preventing the emergence of breast cancer over the long term, but that there were still unanswered questions. The populatio…
…
continue reading
1
Three-Node Breast Cancer Spread: Most Patients Can Safely Avoid Axillary Dissection
9:42
9:42
Spela senare
Spela senare
Listor
Gilla
Gillad
9:42
Most patients whose breast cancer has spread to more than three lymph nodes can nevertheless be spared extensive axillary dissection, according to the findings of a study presented at the 2024 European Breast Cancer Conference in Amsterdam, The Netherlands. Annemiek van Hemert, a Medical Doctor and PhD candidate at the Surgical Oncology Department …
…
continue reading
1
Artificial Intelligence Tool Predicts Postoperative Radiotherapy Lymphedema
34:36
34:36
Spela senare
Spela senare
Listor
Gilla
Gillad
34:36
Artificial intelligence is being harnessed by a team of researchers at Leicester University in the United Kingdom to predict the risk of lymphedema (and potentially other toxicities) from the use of postoperative radiation therapy for breast cancer. The 2024 European Breast Cancer Conference heard the latest news on an artificial intelligence tool …
…
continue reading
1
Neoadjuvant Pembrolizumab Improves High-Risk Early Breast Cancer Outcomes
8:47
8:47
Spela senare
Spela senare
Listor
Gilla
Gillad
8:47
New data from the Phase III KEYNOTE-756 clinical trial show that adding pembrolizumab immunotherapy to chemotherapy before and after surgery for high-risk breast cancer (which was estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative) resulted in better outcomes for patients regardless of their age or menopaus…
…
continue reading
1
Preoperative Partial Breast Irradiation: Marked Benefit in Low-Risk Breast Cancer
9:00
9:00
Spela senare
Spela senare
Listor
Gilla
Gillad
9:00
Offering MRI-guided partial breast irradiation before surgery to patients with low-risk breast cancer could become the norm, according to Yasmin Civil, MD, in the Department of Radiation Oncology at the Amsterdam UMC in the Netherlands, who reported 5-year results from the ABLATIVE trial to the 14th European Breast Cancer Conference. The researcher…
…
continue reading
1
Adjuvant Atezolizumab: No Survival Benefit in Triple-Negative Breast Cancer
9:35
9:35
Spela senare
Spela senare
Listor
Gilla
Gillad
9:35
Adding checkpoint inhibition immunotherapy to adjuvant chemotherapy did not improve survival among patients with triple-negative breast cancers. These findings from a study reported at the 14th European Breast Cancer Conference were presented by Heather McArthur, MD, MPH, Clinical Director of Breast Cancer and Komen Distinguished Chair in Clinical …
…
continue reading
1
01_14 Ampullary Carcinoma (Mini Discussion)
10:59
10:59
Spela senare
Spela senare
Listor
Gilla
Gillad
10:59
1. Clinical presentation and work-up 2. Intestinal and pancreatobiliary subtypes 3. Role of perioperative therapy 4. Considerations for metastatic disease Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by A…
…
continue reading
1
Gene Test Shows Which Triple-Negative Breast Cancers Do Not Need Pre-Op Pembrolizumab
15:44
15:44
Spela senare
Spela senare
Listor
Gilla
Gillad
15:44
About a quarter of all patients with newly diagnosed triple-negative breast cancer will not benefit from neoadjuvant checkpoint inhibitor immunotherapy with an agent such as pembrolizumab—even though it improves outcomes among the remaining majority. At the 14th European Breast Cancer Conference, held in Milan, Italy, Laura van ’t Veer, PhD, Progra…
…
continue reading
1
Triple Therapy for Patients With Mutated FLT3 Gene in Acute Myeloid Leukemia
20:15
20:15
Spela senare
Spela senare
Listor
Gilla
Gillad
20:15
An early study of patients (Phase I/II) with acute myeloid leukemia found that a new three-drug combination therapy greatly improved outcomes—both in patients with relapsed or refractory disease and as initial therapy. The new research involved adding quizartinib that targets fms-related tyrosine kinase 3 (FLT3) oncogene. Mutations of FLT3 are pres…
…
continue reading
1
Important Mantle Cell Lymphoma Findings From the Sympatico Study
13:55
13:55
Spela senare
Spela senare
Listor
Gilla
Gillad
13:55
How best to treat patients with relapsed or refractory mantle cell lymphoma has been made clearer by a report from the multinational Phase III Sympatico Study, presented at the 65th ASH Annual Meeting and Exposition held in San Diego. Lead author Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at the University of Texas MD Ander…
…
continue reading
1
World’s Largest Prostate Cancer Trial, STAMPEDE, Celebrates 20 Years of Progress
17:44
17:44
Spela senare
Spela senare
Listor
Gilla
Gillad
17:44
2024 is the 20th year of clinical studies conducted as part of the STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) trial, a series of investigational approaches to initial therapy for patients with high-risk prostate cancer. Patient accrual has now ended, but practice-changing data continue to eme…
…
continue reading
1
Doublet Inhibitor Therapy Restrains Metastatic EGFR-Mutated NSCLC Progression
16:00
16:00
Spela senare
Spela senare
Listor
Gilla
Gillad
16:00
The multicenter RAMOSE randomized clinical trial has found that doublet growth factor tyrosine kinase inhibitor therapy, when compared with standard osimertinib monotherapy, achieved a statistically significant improvement in progression-free survival in patients whose advanced non-small cell lung cancers were driven by mutated epidermal growth fac…
…
continue reading
1
Gene-Targeted Agent Brings Clinical Benefit in R/R Acute Leukemias
24:23
24:23
Spela senare
Spela senare
Listor
Gilla
Gillad
24:23
A new targeted drug, revumenib, was found to increase response rates and survival in patients whose previously treated acute leukemias relapsed or were refractory to treatment. A Phase II clinical study found revumenib met its primary endpoint and was stopped early because of a high patient response rate and clinical efficacy. Revumenib acts on the…
…
continue reading
1
INTERLACE Study Boosts Cervical Cancer Survival
18:14
18:14
Spela senare
Spela senare
Listor
Gilla
Gillad
18:14
A marked improvement in the outlook for patients with locally advanced cervical cancer has been achieved thanks to a neoadjuvant regimen using standard anti-cancer drugs added to usual therapy. At the ESMO Congress 2023 held in Madrid, Spain, Mary McCormack, PhD, MBBS, FRCR, Consultant Clinical Oncologist at University College London Hospitals, rep…
…
continue reading
1
04_04 Castrate Resistant Metastatic Prostate Cancer
24:50
24:50
Spela senare
Spela senare
Listor
Gilla
Gillad
24:50
1. On continuation of ADT and ARAT switch 2. Systemic therapy options after progression 3. Improper mandated crossover 4. PARP inhibitors in prostate cancer Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by…
…
continue reading
1
RET Fusion-Targeted Drug Doubles Progression-Free Survival in NSCLC Patients
18:43
18:43
Spela senare
Spela senare
Listor
Gilla
Gillad
18:43
Patients whose advanced non-small cell lung cancers harbor the RET gene fusion should receive initial treatment with the RET-targeted agent selpercatinib rather than chemotherapy or chemotherapy combined with immunotherapy. This clear message comes from the randomized Phase III LIBRETTO-431 study reported at ESMO Congress 2023 by Herbert Ho Fung Lo…
…
continue reading
1
Afatinib Recommended for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations
8:33
8:33
Spela senare
Spela senare
Listor
Gilla
Gillad
8:33
The preferred first-line treatment for patients with uncommon sensitizing mutations in tumor epidermal growth factor receptor (EGFR) should now be the tyrosine kinase inhibitor (TKI) afatinib, rather than osimertinib, according to Japanese researchers reporting the ACHILLES trial results at the ESMO Congress 2023 held in Madrid. OncTimesTalk corres…
…
continue reading
1
Adjuvant Radiotherapy No Benefit After Radical Prostatectomy
15:24
15:24
Spela senare
Spela senare
Listor
Gilla
Gillad
15:24
Patients with high-risk prostate cancer who have been treated with radical prostatectomy gain no additional advantage and face extra toxicity if they choose to have adjuvant radiotherapy. That’s according to the findings of the randomized RADICALS study, reported at the ESMO Congress 2023. These results support the use of early salvage radiotherapy…
…
continue reading
1
Collagen-Bound Interleukin 12 Converts “Cold” Tumors Into “Hot” Ones
14:51
14:51
Spela senare
Spela senare
Listor
Gilla
Gillad
14:51
Although immunotherapies for patients with solid tumors such as melanoma can be dramatically successful, the majority of patients are resistant and require alternative treatments. While the cytokine interleukin-12 is well known for potentiating the effect of immunotherapies, such as checkpoint blockade, it couldn’t be used because of toxicity. At t…
…
continue reading
1
Best Gems & Highlights of 2023: Part 1 | EP 53
25:24
25:24
Spela senare
Spela senare
Listor
Gilla
Gillad
25:24
This is Part One of a two-part series where we revisit the most inspiring stories and insights from our episodes in 2023. From courageous journeys to triumphant victories, we honor the resilience and wisdom of real cancer patients and survivors. Amidst these powerful narratives, we also pay tribute to those who have left an indelible mark on our he…
…
continue reading
1
Allogeneic Transplant for AML: Only in Patients Negative for Molecular Minimum Residual Disease
15:43
15:43
Spela senare
Spela senare
Listor
Gilla
Gillad
15:43
The process of identifying which patients with acute myeloid leukemia (AML) can benefit from allogeneic stem cell transplantation in first complete remission (CR1) has taken a step forward thanks to analysis of the UK NCRI AML17 and AML19 studies, reported at the 65th ASH Annual Meeting and Exposition. Patients who achieved molecular residual disea…
…
continue reading
1
Antibody-Drug Conjugate Brings Success in High-Risk R/R Follicular Lymphoma
22:11
22:11
Spela senare
Spela senare
Listor
Gilla
Gillad
22:11
With no standard-of-care treatment for patients with high-risk relapsed/refractory follicular lymphoma, promising remissions have been observed in a Phase II study reported at the 65th ASH Annual Meeting and Exposition. The antibody-drug conjugate loncastuximab tesirine in combination with rituximab brought a very high complete metabolic response r…
…
continue reading
1
04_03 Metastatic Castrate Sensitive Prostate Cancer
29:02
29:02
Spela senare
Spela senare
Listor
Gilla
Gillad
29:02
1. The chemotherapy revolution in prostate cancer 2. Role of ARATs in earlier disease states 3. Triple therapy (chemotherapy, ADT, and ARAT) 4. Considerations for frailer patients with indolent disease Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highl…
…
continue reading
1
Pirtobrutinib After Covalent BTK Inhibitor - Double Refractory CLL
12:16
12:16
Spela senare
Spela senare
Listor
Gilla
Gillad
12:16
Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase (BTK) inhibitor treatment, and new therapeutic options are needed. Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor, was designed to re-establish BTK inhibition.…
…
continue reading
1
Relapsed or Refractory CLL - With Sameer A. Parikh, MBBS, and Alessandra Ferrajoli, MD
12:32
12:32
Spela senare
Spela senare
Listor
Gilla
Gillad
12:32
In a multinational, Phase III, head-to-head trial, ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater specificity, as treatment for relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In prespecified interim analyses, zanubrutinib was superio…
…
continue reading
1
CLL Frontline Treatment - With Sameer A. Parikh, MBBS, & Alessandra Ferrajoli, MD
14:40
14:40
Spela senare
Spela senare
Listor
Gilla
Gillad
14:40
Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking.
…
continue reading
1
04_02 Adjuvant Options for Prostate Cancer
28:41
28:41
Spela senare
Spela senare
Listor
Gilla
Gillad
28:41
1. Physiology, efficacy and toxicities of androgen deprivation 2. Evidence for adjuvant intervention after definitive surgery or radiation 3. Role of abiraterone in high-risk localized prostate cancer 4. Limited evidence to support definitive salvage approach Citations As always, citations, and sources include education from our respective training…
…
continue reading
1
Bouncing Back: Insights On Resilience From Your Cancer Guy | EP 52
29:38
29:38
Spela senare
Spela senare
Listor
Gilla
Gillad
29:38
Join me, Kenny Perkins as I share insights on bouncing back from challenges, and what I have learned over the years from cancer patients. Explore resilience, overcome difficulties, and discover practical tips for navigating through tough times. I reflect on developing resilience, encouraging you to ponder your own ability to bounce back. Tune in fo…
…
continue reading
1
04_01 Fundamentals of Localized Prostate Cancer
31:59
31:59
Spela senare
Spela senare
Listor
Gilla
Gillad
31:59
1. Background and presentation of prostate Cancer 2. Evidence behind PSA screening and hallmarks of a screening test 3. Staging and risk stratification of Localized Disease 4. Management options and the ProtecT Trial Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodat…
…
continue reading
1
04_00 Introduction (Updated 12.17.23)
3:38
3:38
Spela senare
Spela senare
Listor
Gilla
Gillad
3:38
We have updated our initial introduction and are re-posting it here as well as in the initial file.Av Talking About Tumors
…
continue reading
1
Youtube Coach Battles Cancer: Owen’s Unfiltered Story | EP 51
1:12:05
1:12:05
Spela senare
Spela senare
Listor
Gilla
Gillad
1:12:05
In this episode, we engage in a powerful and insightful conversation with Owen, a YouTube coach and cancer survivor. Together, we explore Owen's inspiring journey on how faced cancer twice, he emphasizes the significance of a strong support system and discusses the emotional challenges he encountered. Throughout our discussion, we dive into themes …
…
continue reading
1
Sabestomig in Non-Small Cell Lung Cancer: Bi-Specific Antibody Safe and Active
11:10
11:10
Spela senare
Spela senare
Listor
Gilla
Gillad
11:10
Patients with non-small cell lung cancer who have failed initial immunotherapy therapy with anti-programmed cell death ligand-1 (PDL-1) checkpoint inhibitors, have responded to a new “bispecific” antibody that targets both the programmed cell death-1 (PD-1) antibody and also the T-cell immunoglobulin and mucin domain 3 (TIM-3) molecule. Benjamin Be…
…
continue reading
1
03_13 Head and Neck Cancer – Locally advanced and metastatic
37:18
37:18
Spela senare
Spela senare
Listor
Gilla
Gillad
37:18
1. Role for definitive chemotherapy and radiation 2. Controversy on induction chemotherapy 3. Considerations for nasopharyngeal cancer 4. Approach to metastatic HNSCC Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines pu…
…
continue reading
1
Radicals Study Finds Adjuvant Radiotherapy No Benefit After Radical Prostatectomy
15:23
15:23
Spela senare
Spela senare
Listor
Gilla
Gillad
15:23
Patients with high-risk prostate cancer who have been treated with radical prostatectomy gain no additional advantage and face extra toxicity if they choose to have adjuvant radiotherapy. That’s according to the findings of the randomized RADICALS study, reported at the 2023 annual congress of the European Society for Medical Oncology (ESMO) held i…
…
continue reading
1
Two Drug Combination Benefits Patients with nRAS-Mutated Melanoma Refractory to Checkpoint Inhibition
13:38
13:38
Spela senare
Spela senare
Listor
Gilla
Gillad
13:38
Research presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics found that a combination of two drugs targeting the nRAS mutation had clinical activity in patients with checkpoint-inhibitor refractory melanoma and had potential for treating other solid tumors with mutated nRAS as their oncogenic d…
…
continue reading
1
Collagen-Bound Interleukin 12 Converts “Cold” Tumors into “Hot” Ones
14:50
14:50
Spela senare
Spela senare
Listor
Gilla
Gillad
14:50
Although immunotherapies for patients with solid tumors such as melanoma can be dramatically successful, the majority of patients are resistant and require alternative treatments. While the cytokine interleukin 12 is well known for potentiating the effect of immunotherapies, such as checkpoint blockade, it could not be used because of toxicity. At …
…
continue reading
1
Double TKI Therapy Improves Responses in MET Amplification-Driven EGFR-Mutant Non-Small Cell Lung Cancer
15:22
15:22
Spela senare
Spela senare
Listor
Gilla
Gillad
15:22
Among patients with non-small cell lung cancers driven by mutations in the epidermal growth factor receptor (EGFR), those with MET-amplification can now be selected for therapy with two tyrosine kinase inhibitor drugs, not just standard osimertinib. That’s according to conclusions from the INSIGHT 2 study reported at the AACR-NCI-EORTC internationa…
…
continue reading
1
CLIC Protein Inhibition Key to Metformin’s Anti-Neoplastic Properties
24:17
24:17
Spela senare
Spela senare
Listor
Gilla
Gillad
24:17
The Chloride Intracellular Channel 1 (CLIC1) protein appears to hold the key to understanding the anti-proliferative action of metformin, according to laboratory evidence discussed at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in October 2023, in Boston. At the conference, Michele M. Mazzanti, PhD,…
…
continue reading
1
Adjuvant ATR Inhibition Prolonged Life in Patients with Relapsed Small Cell Lung Cancer
18:59
18:59
Spela senare
Spela senare
Listor
Gilla
Gillad
18:59
Dr. Takahashi talks with OncTimes Talk’s Peter Goodwin about the Phase 2 study he presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 11 - 15, 2023. Dr. Takahashi reported an improvement in median overall survival among patients with relapsed small cell lung cancer who had the ATR inhibitor…
…
continue reading
1
Mitophagy Discovered as Potential Reason for AML’s Resistance to Venetoclax
15:20
15:20
Spela senare
Spela senare
Listor
Gilla
Gillad
15:20
Acute myeloid leukemia (AML) is notoriously difficult to treat. Only 28 percent of patients survive beyond 5 years after diagnosis. Mitophagy, a process in which damaged mitochondria are eliminated to prevent the transmission of death signals, has been identified as a key mechanism that allows leukemia cells to resist the effects of the widely pres…
…
continue reading
1
Empowerment Down Under: Meet Helen Beeley from Brisbane | EP 50
48:15
48:15
Spela senare
Spela senare
Listor
Gilla
Gillad
48:15
In this episode, our guest, Helen Beeley, shares her remarkable journey, emphasizing the power of determination, a positive outlook, and the unwavering human spirit. Helen inspires us with her story. Her experiences serve as a beacon of hope, reminding us that with the right mindset, support, self-care, and resilience, we can overcome life's challe…
…
continue reading
1
03_12 Head and Neck Cancer – Background and adjuvant considerations
23:28
23:28
Spela senare
Spela senare
Listor
Gilla
Gillad
23:28
1. Anatomy, diagnostic work-up and staging 2. Field cancerization 3. Indications for adjuvant concurrent chemoradiation 4. Evidence to support weekly cisplatin with concurrent radiation Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage revi…
…
continue reading
1
A Tribute to a Remarkable Soul: Jessie Lee’s Cancer Journey | EP 49
56:06
56:06
Spela senare
Spela senare
Listor
Gilla
Gillad
56:06
In this episode, we honor the memory of Jessie Lee, in her battle with colon cancer. Her inspiring journey, filled with resilience and positivity, serves as a beacon of hope. Join us as we revisit her story and celebrate her enduring spirit. This is an episode you do not want to miss. Subscribe and share with others who may find strength and inspir…
…
continue reading
1
03_11 Mesothelioma and a bit of Large Cell Neuroendocrine Carcinoma
29:40
29:40
Spela senare
Spela senare
Listor
Gilla
Gillad
29:40
1. Presentation, and considerations for regional mesothelioma 2. Systemic therapy options for advanced mesothelioma 3. Corticosteroids for pemetrexed, paclitaxel and docetaxel 4. A quick review on considerations for LCNEC Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Up…
…
continue reading